A Study in Healthy Volunteers to Investigate How Much Test Medicine [14C]-Uproleselan is Taken up by the Body When Administered Directly Into the Vein (IV)
An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Uproleselan Administered Via the Intravenous Route to Healthy Subjects (ADME Study of IV [14C]-Uproleselan in Healthy Subjects)
Sponsor: GlycoMimetics Incorporated
This PHASE1 trial investigates Healthy Subjects and is currently completed. GlycoMimetics Incorporated leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2018 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE1
-
Aug 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlycoMimetics Incorporated
- Quotient Sciences
For direct contact, visit the study record on ClinicalTrials.gov .